What is Omniscan Prefill Plus
Omniscan Prefill Plus is an injection that contains the drug gadolinium as the active ingredient. Gadolinium is a contrast agent that is used to improve the visibility of certain body tissues during a scan. Omniscan Prefill Plus is used to improve the visibility of certain body tissues during a scan.
Benefits of Omniscan Prefill Plus
and Its Uses.
Omniscan Prefill Plus is a gadolinium-based contrast agent (GBCA) used in magnetic resonance imaging (MRI) to improve the visibility of certain tissues or organs. Omniscan is available as a generic drug and as the brand-name drug Omniscan Prefill Plus.
Gadolinium-based contrast agents have been linked to the development of a rare but serious condition called nephrogenic systemic fibrosis (NSF), a debilitating and sometimes fatal disease. However, the risk of developing NSF appears to be very low, and the benefits of using a GBCA generally outweigh the risks.
If you’re considering having an MRI and you’re worried about the potential for developing NSF, talk to your doctor about the risks and benefits of using a gadolinium-based contrast agent.
Side Effects and Dosage of Omniscan Prefill Plus
Omniscan Prefill Plus is a gadolinium-based MRI contrast agent used to improve the visibility of images of the body’s organs and tissues. It is used to help diagnose diseases or conditions, such as cancer, and to help assess the severity of certain injuries. Omniscan Prefill Plus is given by injection into a vein (IV).
The most common side effects of Omniscan Prefill Plus are headache, nausea, and vomiting.
Omniscan Prefill Plus can cause a serious allergic reaction. Stop using Omniscan Prefill Plus and get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Omniscan Prefill Plus can also cause a serious kidney problem, especially if you are elderly, have diabetes, or have preexisting kidney problems. Call your doctor right away if you have any of the following